Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Salarius Pharmaceuticals, Inc. Director's Dealing 2019

Sep 13, 2019

35494_dirs_2019-09-12_daa7e6fc-61a3-4fae-9078-9780cbfc959d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2019-09-10

Reporting Person: McVicar William K. (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-09-10 Stock Option (right to buy) $8.0 A 3000 Acquired 2029-09-10 Common Stock (3000.0) Direct

Footnotes

F1: On July 19, 2019, the Issuer effected a 1-for-25 reverse stock split of its then outstanding common stock, resulting in the reporting person's ownership of 34,385 options.